PVCT · XBRL financial data

Provectus Biopharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PVCT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	70	121*	238	255	110	14*	279	57	0*	0*	—	—
Research and development	351	416*	556	473	414	557*	389	867	346	268*	333	131
General and administrative	433	310*	130	577	651	1,792*	988	991	930	852*	915	808
Total operating expenses	784	726*	685	1,050	1,065	2,349*	1,377	1,858	1,276	1,120*	1,248	939
Operating income (loss)	(714)	(605)*	(447)	(795)	(956)	(2,335)*	(1,098)	(1,801)	(1,276)	(1,120)*	(1,248)	(939)
Interest expense	—	year only	—	—	—	year only	64	51	—	year only	53	50
Net income (loss)	(776)	(663)*	(504)	(847)	(1,014)	(2,367)*	(1,140)	(1,814)	(1,311)	(1,165)*	(1,290)	(983)
Earnings per share, basic USD per share	0.00	0.00*	0.00	0.00	0.00	(0.01)*	0.00	0.00	0.00	0.00*	0.00	0.00
Earnings per share, diluted USD per share	0.00	0.00*	0.00	0.00	0.00	(0.01)*	0.00	0.00	0.00	0.00*	0.00	0.00
Weighted average shares, basic thousands of shares	419,516	419,522*	419,522	419,522	419,907	420,283*	420,280	420,280	420,280	420,280*	420,280	420,280
Weighted average shares, diluted thousands of shares	419,516	419,522*	419,522	419,522	419,907	420,283*	420,280	420,280	420,280	420,280*	420,280	420,280

Fiscal quarters (PVCT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	367	77	18	30	187	307	390	386	72	251	224	1,157
Prepaid and other current assets	181	338	246	210	146	487	180	152	206	317	237	212
Total current assets	1,592	1,365	1,009	800	760	977	649	568	278	568	460	1,369
Property and equipment, net	14	12	10	8	5	5	4	4	3	3	3	2
Right-of-use asset	84	72	60	49	37	25	12	150	138	127	115	103
Total assets	1,690	1,449	1,079	856	802	1,006	666	722	420	698	578	1,474
Accounts payable	1,785	1,676	1,370	1,322	1,381	1,107	744	1,311	1,178	716	815	932
Total current liabilities	9,172	9,017	8,516	8,370	6,225	6,975	5,735	6,493	6,472	6,897	7,242	7,707
Lease liability, non-current	38	25	13	—	—	—	—	104	92	79	67	54
Total liabilities	9,209	9,042	8,529	8,370	6,225	6,975	5,735	6,597	6,587	7,000	7,308	7,761
Accumulated deficit	(252,027)	(252,690)	(253,194)	(254,041)	(255,056)	(257,423)	(258,563)	(260,377)	(261,689)	(262,854)	(264,144)	(265,127)
Total stockholders' equity	(7,519)	(7,593)	(7,450)	(7,513)	(5,423)	(5,959)	(5,103)	(5,871)	(6,151)	(6,299)	(6,725)	(6,275)
Total liabilities and equity	1,690	1,449	1,079	856	802	1,006	666	722	420	698	578	1,474
Common shares outstanding (cover page) thousands of shares	419,522	419,522	419,522	419,907	420,280	420,280	420,280	420,280	420,280	420,280	420,280	420,280

Fiscal quarters (PVCT's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(776)	(663)*	(504)	(847)	(1,014)	(2,367)*	(1,140)	(1,814)	(1,311)	(1,165)*	(1,290)	(983)
Stock-based compensation	—	0*	—	—	—	year only	315	322*	313*	288*	306	306*
Net cash from operating activities	(769)*	(561)*	(1,044)	(763)*	(565)*	(912)*	(1,093)	(523)*	(840)*	(870)*	(358)	(358)*
Proceeds from issuing common stock	—	—	—	—	—	—	700	0*	—	—	75	0*
Net cash from financing activities	818*	202*	781	589*	589*	788*	1,073	470*	496*	1,048*	330	1,291*
Net change in cash	51*	(383)*	(264)	(173)*	25*	(124)*	(20)	(53)*	(344)*	179*	(27)	933*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.